Privacy preference
MEDtalks would like to keep you informed about the content that is most relevant to you. Click
here
for more information.
Yes
No
Back
Toevoeging van pembrolizumab aan de tweedelijnsbehandeling van TKI-resistent EGFR-mutant NSCLC (Keynote-789)
Chat with us
, powered by
LiveChat